Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
HOME > COMMENTARY
COMMENTARY
- Delicate Balancing Act Required for SGLT-2 Inhibitor Promotions - Safety vs Efficacy
June 16, 2014
- Why Not Make RMPs for Existing Products as Differentiation Strategy?
June 9, 2014
- 2013 Earnings Signal Foreign Drug Makers Losing Steam in Japan
June 2, 2014
- Clinical Research Regulations at Crossroads: Guidelines or Legislation?
May 26, 2014
- Was the Main Paper from VART Study “Practice” for a Grad Student?
May 19, 2014
- Can CROs Become Independent Players? Compliance, Ethics Will Be Major Issues for Growing Industry
April 28, 2014
- Industry Faces Tough Road to Institutionalization of Key Premium, Eligibility Up for Discussion
April 21, 2014
- Approval of Novel Antiepileptic Drugs as Monotherapies Coming Closer to Reality
April 7, 2014
- Will Japan NIH Initiative Create a “Japanese Model” that Overcomes Its Size Disadvantage?
March 28, 2014
- CASE-J Flutter: Doesn’t Blopress Ad Overemphasize Its Benefits on Diabetes?
March 19, 2014
- “Lack of Urgency” Leads to New Rule; Penalty for Low Price Settlement Rates May Have Been Inevitable
March 12, 2014
- Hardships and Successes of Diversified Entrants Lead to Question: Will Pharmaceuticals Continue to Be a Growth Sector?
March 5, 2014
- Revised JCS Guidelines Clarify Role of Novel Oral Anticoagulants in Patients with Atrial Fibrillation
February 12, 2014
- Will JPWA’s Move to Integrate Tax Display Method Dispel Medical Institutions’ Misconception?
January 31, 2014
- FY2014 May Be Year 1 of New Reform Era; Drug Makers Need to “Turn Calamity into Good Fortune”
January 7, 2014
- First SGLT-2 Inhibitor Set to Debut Next April; Curtain Rising on “Unprecedentedly Competitive” Market
December 18, 2013
- Bearing “Edo” in Its Name, Japan-Originated Edoxaban Set to Challenge Rival Anticoagulants in World Market
December 6, 2013
- MHLW Shocks Generic Drug Industry by Proposing “50% Rule,” Expansion of Uniform Pricing
November 19, 2013
- Range of Drugs Eligible for Premium for New Drug Development May Be Reviewed; Industry Needs to Dispel Suspicions
November 13, 2013
- Interim Report of Diovan Committee Raises Further Questions
October 15, 2013
ページ
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…